Bridgeway Capital Management’s Elevation Oncology ELEV Stock Holding History

Bridgeway Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-95,963	Closed	-$54K	–	1200
2024 Q4	$54K	Sell	95,963 -32,037	-25%	-$18.9K	﹤0.01%	1151
2024 Q3	$76.8K	Hold	128,000	–	–	﹤0.01%	1179
2024 Q2	$346K	Buy	128,000 +21,500	+20%	+$81K	0.01%	940
2024 Q1	$546K	Buy	+106,500	New	+$345K	0.01%	900
2023 Q4	–	Sell	-56,500	Closed	-$37.4K	–	1375
2023 Q3	$37.4K	Hold	56,500	–	–	﹤0.01%	1324
2023 Q2	$85.9K	Hold	56,500	–	–	﹤0.01%	1279
2023 Q1	$107K	Sell	56,500 -78,000	-58%	-$101K	﹤0.01%	1225
2022 Q4	$127K	Hold	134,500	–	–	﹤0.01%	1183
2022 Q3	$152K	Sell	134,500 -22,000	-14%	-$27.7K	﹤0.01%	1191
2022 Q2	$219K	Buy	156,500 +100,000	+177%	+$251K	0.01%	1075
2022 Q1	$142K	Buy	+56,500	New	+$227K	﹤0.01%	1227

Other funds holding ELEV

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's ELEV Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 95,963 shares — an estimated $54K sold.

Bridgeway Capital Management first reported a position in ELEV in Q1 2022 and held it in 11 quarters. The position peaked at $546K in Q1 2024. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

Bridgeway Capital Management reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
Bridgeway Capital Management sold 95,963 Elevation Oncology shares in Q1 2025, an estimated $54K.
Bridgeway Capital Management first reported a position in Elevation Oncology in Q1 2022 and held it in 11 quarters.
Bridgeway Capital Management's Elevation Oncology position peaked at $546K in Q1 2024.
72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.